Evidence map›Paper›PMID 42292303›Full record

ArticleInternational journal of pharmaceutics: X2026

Resiquimod-loaded magnetic nanoparticles reprogram macrophages and induce oxidative cytotoxicity against triple-negative breast cancer cells.

Kamonlatth Rodponthukwaji, Ladawan Khowawisetsut, Nathachit Limjunyawong, Sith Sathornsumetee, Chatchawan Srisawat, Numpon Insin, Tam Nguyen, Primana Punnakitikashem

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kamonlatth RodponthukwajiSiriraj Center of Research Excellence in Theranostic Nanomedicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
Ladawan KhowawisetsutDepartment of Parasitology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
Nathachit LimjunyawongSiriraj Center of Research Excellence in Allergy and Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
Sith SathornsumeteeSiriraj Center of Research Excellence in Theranostic Nanomedicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
Chatchawan SrisawatSiriraj Center of Research Excellence in Theranostic Nanomedicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
Numpon InsinDepartment of Chemistry, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand.
Tam NguyenDepartment of Bioengineering, University of Texas at Arlington, Arlington, TX 76019, USA.
Primana PunnakitikashemSiriraj Center of Research Excellence in Theranostic Nanomedicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of alternative cancer therapies remains a critical priority to overcome the significant adverse effects associated with conventional chemotherapy. Accordingly, innovative strategies are required to mitigate chemotherapy-induced toxicity. Among these, reprogramming the immunosuppressive tumor microenvironment into an immunostimulatory state has emerged as a promising approach; however, single-modality approaches often underperform. In this work, we engineered resiquimod (

Indexed as

Lipid peroxidationMacrophage polarizationMagnetic nanoparticleReactive oxygen speciesResiquimodTriple-negative breast cancer

Identifiers

PMID42292303
PMCPMC13254843

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.